CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 130 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $17,440,000 | -4.0% | 4,000,000 | 0.0% | 0.62% | -0.2% |
| Q1 2021 | $18,160,000 | -20.9% | 4,000,000 | 0.0% | 0.62% | -16.5% |
| Q4 2020 | $22,960,000 | -20.7% | 4,000,000 | 0.0% | 0.74% | -26.3% |
| Q3 2020 | $28,960,000 | +314.9% | 4,000,000 | +100.0% | 1.00% | +226.1% |
| Q2 2020 | $6,980,000 | +135.8% | 2,000,000 | 0.0% | 0.31% | +52.0% |
| Q1 2020 | $2,960,000 | -24.5% | 2,000,000 | 0.0% | 0.20% | -9.0% |
| Q4 2019 | $3,920,000 | -38.8% | 2,000,000 | +60.0% | 0.22% | -52.2% |
| Q3 2019 | $6,400,000 | -28.5% | 1,250,000 | 0.0% | 0.46% | -39.7% |
| Q2 2019 | $8,950,000 | -46.1% | 1,250,000 | 0.0% | 0.77% | -59.9% |
| Q1 2019 | $16,600,000 | +0.7% | 1,250,000 | -40.3% | 1.92% | -5.7% |
| Q4 2018 | $16,480,000 | -29.0% | 2,094,000 | 0.0% | 2.04% | -20.9% |
| Q3 2018 | $23,202,000 | -17.4% | 2,094,000 | 0.0% | 2.58% | -19.1% |
| Q2 2018 | $28,101,000 | -20.3% | 2,094,000 | -22.8% | 3.18% | -15.4% |
| Q1 2018 | $35,242,000 | +278.2% | 2,712,986 | +167.8% | 3.76% | +120.9% |
| Q4 2017 | $9,319,000 | +14.1% | 1,012,986 | 0.0% | 1.70% | -8.4% |
| Q3 2017 | $8,165,000 | +233.5% | 1,012,986 | +138.3% | 1.86% | +219.4% |
| Q2 2017 | $2,448,000 | -26.8% | 425,000 | -45.3% | 0.58% | -20.3% |
| Q1 2017 | $3,342,000 | – | 777,202 | – | 0.73% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |